Cenicriviroc Mesylate (formerly known as TAK-652 Mesylate or TBR-652 Mesylate) is a novel, orally bioactive, and dual antagonist of CCR2/CCR5, it also inhibits both HIV-1 and HIV-2, and has the potential for the treatment of HIV infection.

Vercirnon (formerly also known as CCX282-B and GSK1605786) is a novel, potent, orally bioavailable, selective antagonist of CCR9 with an IC50 of 10 nM, used in the research of inflammatory bowel diseases.

AZD 4818 (AZD-4818) is a novel and potent chemokine recptor CCR1 antagonist with the potential to be used for the treatment of COPD/chronic obstructive pulmonary disease.